Introduction
Developing individuals (embryos, fetuses, newborns, infants, children, and adolescents) are a uniquely susceptible population to insults from environmental hazards (1, 2) . Their increased susceptibility can arise from increased exposure to environmental toxins, increased exposure of individual organ systems from differences in distribution of toxins, immaturity of metabolic pathways, immaturity of excretory pathways, alterations in target organ susceptibility, and a longer life span in which to express illness. Although the enhanced susceptibility of infants and children to environmental toxicants has been shown in multiple studies, the nature and extent of pediatric illness secondary to environmental exposure has not been well characterized. There are several reasons for this deficiency. First, documentation of exposure is difficult in the fetal and pediatric population. Pregnant women and children do not wear personal monitoring devices as do workers in an occupational exposure setting. Modeling of exposure is difficult; there are few studies documenting where children spend their time. Even in situations with known exposures, the individual dose to a child is difficult to document. The Frequently the disease state presents following birth, when common environmental exposures occur. Such disease states are easily recognized because of their acuity and severity, for example, xeroderma pigmentosa and skin cancer from UV irradiation (inability to repair DNA damage), phenylketonuria and a diet with phenylalanine-containing proteins (inability to metabolize phenylalanine), or glucose 6-phosphate dehydrogenase deficiency and methemoglobinemia from exposure to naphthalene mothballs (inability to reduce the oxidized iron in hemoglobin). More difficult to detect are those genetic variations leading to genetic susceptibility in individuals with common genetic polymorphisms. They are common because either the increased susceptibility is to a rare environmental exposure, or the disease states are of a more chronic or subacute nature. For example, only newborns unable to metabolize dilantin delivered to mothers taking dilantin (a rare exposure) had features of phenytoin embryopathy. A biomarker of this susceptibility is the epoxide hydrolase activity of fetal amniocytes (18) . Recent advances in determining genetic susceptibility are discussed by Suk and Collman (19) and Whyatt et al. (20) in this issue.
Validation of Biologic Markers
To validate the use of a biologic measurement as a biomarker, it is necessary to understand the relationship between the marker and the event or condition of interest. Determining the sensitivity and specificity are critical components of the validation process. Sensitivity refers to the ability of a test to correctly identify those with the condition or disease of interest. Specificity refers to the ability of a test to correctly identify those without the condition or disease of interest. Biomarkers of exposure or effect must be validated in terms of their ability to assess the true exposure or disease (sensitivity) and their ability to assess the lack of exposure or disease (specificity). One of the primary purposes of biomarkers in environmental health research is to identify exposed persons, so that risk can be predicted and disease prevented. Validation of biomarkers includes the backward process of associating a biomarker with exposure, and the forward process of linking a biomarker with effect. Appropriate validation for a biomarker depends on its anticipated use. A biomarker observed well before the onset of disease may have a low predictive value as a biomarker of effect, but be very useful as a biomarker of exposure, enabling long-term surveillance of an exposed population. In contrast, a biomarker of effect that is expressed long after exposure could be of relatively little use in exposure assessment, but be very useful in predicting progression of disease or in calculating risk. Animal models are useful for understanding the mechanistic bases of the expression of markers and relationships between exposure, early effects, and disease. The validity of a specific biomarker of effect depends on the reliability of studies that provide the background data, particularly on mechanisms. Estimates of the sensitivity of a biomarker must include its evaluation in an unexposed population or unexposed animals to determine a baseline value for the marker. This evaluation may be difficult in the pediatric population because of ethical issues involving invasive procedures with little benefit to the pediatric participant. Examples of two biomarkers that have been extensively validated for both exposure and effect are blood lead concentrations for both lead exposure and lead neurotoxicity, and cotinine in serum, urine, and saliva for both exposure to environmental tobacco smoke and for predicting reduction in birth weight. Examples of two biomarkers currently in the process of validation include dentin lead levels to predict elevated adult body burden of lead (biomarker of exposure) and reaction 
